XV Technology: A resource multiplier in the national COVID-19 response

COVID-19 – How We Can Help

As the COVID-19 pandemic progresses, our knowledge of the disease and its threat to the respiratory system have been evolving rapidly. The prevalence of Acute Respiratory Distress Syndrome (ARDS) in severe, life-threatening cases of COVID-19 is now well-documented, and it is also evident that COVID-19 may lead to both short and long-term deterioration in patient’s lung function.

XV Technology can play an important role in detecting, mapping and quantifying any loss or improvement of lung function in COVID-19 patients. 4Dx Technology has been applied in preclinical ARDS studies for several years, demonstrating that regional lung ventilation abnormalities associated with ARDS can be identified with high sensitivity1–3. XV Technology has been demonstrated to be a powerful tool for not only gauging the extent of respiratory problems resulting from COVID-19 and other infectious  diseases, but also monitoring improvements or deterioration over longer timescales.

Potential Clinical Use Cases
  • Emergency screening support (in the event that localised demand outstrips capacity)
  • Improved patient triage:
    • As a diagnostic report: XV Technology provides lung function quantification to help determine initial treatment: home rest, admission to a ward or immediate admission to ICU
    • As a surveillance tool: XV Technology provides faster feedback on treatment efficacy. This enables clinicians to make faster decisions in the type/level of patient care (alter treatment plan), and resourcing (e.g. move from ICU to ward)
  • Accelerated therapy research:
    • More sensitive than other tests / scans. Up to 6x faster feedback on changes in lung function
  • Patient lung health monitoring post COVID-19
Health Economics
  • XV Technology is a performance multiplier on other health expenditure as it adds value to every bed and ventilator, with great potential to accelerate therapy R&D. It is also uniquely suited to monitoring the lung health of patients after they have been discharged from hospital.

1. Yen S, Preissner M, Bennett E, et al. The Link between Regional Tidal Stretch and Lung Injury during Mechanical Ventilation. Am J Respir Cell Mol Biol. 2018;60(5):569-577. doi:10.1165/rcmb.2018-0143OC

2. Yen S, Preissner M, Bennett E, et al. Interaction between regional lung volumes and ventilator-induced lung injury in the normal and endotoxemic lung. Am J Physiol Lung Cell Mol Physiol. 2020;318(3):L494-L499. doi:10.1152/ajplung.00492.2019

3. Kim EH, Preissner M, Carnibella R, et al. Novel Analysis of 4DCT Imaging Quantifies Progressive Increases in Anatomic Dead Space During Mechanical Ventilation in Mice. J Appl Physiol. Published online June 8, 2017:jap.00903.2016. doi:10.1152/japplphysiol.00903.2016